publication venue for
- 261 Evidence for durable anti-tumor responses by TAC-T cells in preclinical models of solid tumors 2022
- 538 Comprehensive single cell transcriptomic profiling of untreated resectable lung cancers 2022
- 545 A phase II randomized window of opportunity trial evaluating cytotoxic and immunomodulatory effects of intratumoral INT230-6 (cisplatin, vinblastine) in early stage breast cancer: the INVINCIBLE trial 2022
- 852 Investigating the functional role of GPNMB in glioblastoma and the tumor immune microenvironment and its targeted elimination using CAR-Ts 2022
- 459 Phase 3 study of first-line pembrolizumab with and without vibostolimab (anti-TIGIT) in patients with PD-L1–positive metastatic NSCLC 2021
- 101 Engineering gamma/delta T cells with the T-Cell antigen coupler receptor effectively induces antigen-specific tumor cytotoxicity in vitro and in vivo 2020
- 94 The T cell antigen coupler (TAC) redirects T cell oncolysis while limiting tonic signaling to create a safer engineered T cell product with a higher threshold for activation 2020
- P863 KEYNOTE-022 parts 4 and 5: pembrolizumab plus trametinib for patients with solid tumors or BRAF wild-type melanoma 2020
- Conditional immune toxicity rate with immune checkpoint inhibitors 2019
- A novel chimeric T cell receptor that operates through the endogenous TCR diverges in biology from conventional CAR T cells 2017
- Preclinical evaluation of BCMA-specific TAC receptor-engineered T cells for multiple myeloma 2017
- Pyroptosis activates conventional type I dendritic cells to mediate the priming of highly functional anticancer T cells. 12:e006781-e006781. 2024
- TP53/mTORC1-mediated bidirectional regulation of PD-L1 modulates immune evasion in hepatocellular carcinoma. 11:e007479-e007479. 2023
- Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review. 11:e006500-e006500. 2023
- Intrinsic suppression of type I interferon production underlies the therapeutic efficacy of IL-15-producing natural killer cells in B-cell acute lymphoblastic leukemia. 11:e006649-e006649. 2023
- Adaptation of transgene mRNA translation boosts the anticancer efficacy of oncolytic HSV1. 11:e006408-e006408. 2023
- FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy. 10:e005780-e005780. 2022
- Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression. 10:e003923-e003923. 2022
- Oncolytic Orf virus licenses NK cells via cDC1 to activate innate and adaptive antitumor mechanisms and extends survival in a murine model of late-stage ovarian cancer. 10:e004335-e004335. 2022
- CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment. 10:e003289-e003289. 2022
- Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies. 10:e003024-e003024. 2022
- Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma. 10:e003497-e003497. 2022
- 286 Sex differences in the transcriptional profiles of mucosal-associated invariant T cells in neoadjuvant anti-PD-1 treated non-small cell lung cancer (NSCLC). 9:A310-A310. 2021
- 293 Distinct tumor infiltrating treg lineages are associated with response to anti-PD1 checkpoint blockade in non-small cell lung cancer. 9:A317-A317. 2021
- 327 Development and validation of a neoantigen-specific T cell gene signature to identify antitumor T cells in lung cancer and melanoma. 9:a353-a353. 2021
- 665 Transcriptional landscape of tumor-reactive TIL in lung cancer and melanoma. 9:a693-a693. 2021
- CXCR6 by increasing retention of memory CD8+ T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer. 9:e003329-e003329. 2021
- Evaluating T-cell cross-reactivity between tumors and immune-related adverse events with TCR sequencing: pitfalls in interpretations of functional relevance. 9:e002642-e002642. 2021
- Expanded human NK cells from lung cancer patients sensitize patients’ PDL1−negative tumors to PD1-blockade therapy. 9:e001933-e001933. 2021
- Enhanced immunotherapeutic profile of oncolytic virus-based cancer vaccination using cyclophosphamide preconditioning. 8:e000981-e000981. 2020
- Correction: Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. 8:e000337corr1-e000337corr1. 2020
- Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors. 8:e000371-e000371. 2020
- Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. 8:e000337-e000337. 2020
- Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer. 7:189. 2019
- Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. 6:5. 2018
- Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series. 5:66. 2017
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one. 4:1-106. 2016
- Designed ankyrin repeat proteins are effective targeting elements for chimeric antigen receptors. 3:55. 2015
- On-target off-tumor toxicity; when enhancing an NKG2D-based CAR in vitro led to severe toxicities in vivo. 2:P15-P15. 2014
- Tri-functional T cell receptor antigen coupler (Tri-TAC): a novel method to direct T cells against tumors. 2:P17-P17. 2014